Your browser doesn't support javascript.
loading
Current status and future prospects of p38α/MAPK14 kinase and its inhibitors.
Madkour, Moustafa M; Anbar, Hanan S; El-Gamal, Mohammed I.
Affiliation
  • Madkour MM; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates.
  • Anbar HS; Department of Clinical Pharmacy and Pharmacotherapeutics, Dubai Pharmacy College for Girls, Dubai, 19099, United Arab Emirates.
  • El-Gamal MI; College of Pharmacy, University of Sharjah, Sharjah, 27272, United Arab Emirates; Department of Medicinal Chemistry, Faculty of Pharmacy, University of Mansoura, Mansoura, 35516, Egypt. Electronic address: drmelgamal2002@gmail.com.
Eur J Med Chem ; 213: 113216, 2021 Mar 05.
Article in En | MEDLINE | ID: mdl-33524689
ABSTRACT
P38α (which is also named MAPK14) plays a pivotal role in initiating different disease states such as inflammatory disorders, neurodegenerative diseases, cardiovascular cases, and cancer. Inhibitors of p38α can be utilized for treatment of these diseases. In this article, we reviewed the structural and biological characteristics of p38α, its relationship to the fore-mentioned disease states, as well as the recently reported inhibitors and classified them according to their chemical structures. We focused on the articles published in the literature during the last decade (2011-2020).
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase 14 / Protein Kinase Inhibitors / Neoplasms Limits: Animals / Humans Language: En Journal: Eur J Med Chem Year: 2021 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Mitogen-Activated Protein Kinase 14 / Protein Kinase Inhibitors / Neoplasms Limits: Animals / Humans Language: En Journal: Eur J Med Chem Year: 2021 Document type: Article Affiliation country:
...